uniQure N.V. (NASDAQ:QURE)
Industry: Healthcare

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Current Quote*
Last: $37.360
Change: 1.220
Book: $6.981
Volume: 533,067

As Of: 02/15 13:37 ET
*Quotes delayed by 20min.

Graphs for QURE


3 Month Graph


6 Month Graph


1 Year Graph